Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Thalidomide

100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg

DRUG

Doxil

On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00307294 - Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) | Biotech Hunter | Biotech Hunter